2025 Archives - Page 3 of 7

Philogen Management to hold a Webinar to provide an update on Nidlegy™ Marketing Authorization Application in Melanoma.

Jun 25, 2025 | 2025, Events, Investors, Past Events

The Webinar will take place on June 25 at 10:00 ET | 15:00 GMT | 16:00 CET. Please use this link to register to the event or contact us at ir@philogen.com

Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in the European Union

Jun 24, 2025 | 2025, Past Events, Press Releases

More details

Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.

Jun 11, 2025 | 2025, Events, Investors, Past Events

Following last night’s announcement regarding OncoACP3, we are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET. Please contact us at IR@philogen.com or follow the link to register to the...

La controllata Philochem AG ha concesso in licenza i diritti a livello mondiale su OncoACP3, un nuovo agente terapeutico e diagnostico per il trattamento del cancro alla prostata, a RayzeBio, società del gruppo Bristol-Myers Squibb, per un valore fino a 1,35 miliardi di dollari più royalties.

Jun 10, 2025 | 2025, Press Releases

More details

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.

Jun 10, 2025 | 2025, Press Releases

More details

The MedChem division of the Italian Chemical Society (SCI) awarded two Prizes to Philochem employees: Samuele Cazzamalli (Head of Chemistry) and Sara Puglioli (Research Scientist)

May 29, 2025 | 2025, Press Releases

For more details

Philogen Management to hold a Webinar to provide an update on Nidlegy™ Marketing Authorization Application in Melanoma.

Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in the European Union

Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.

La controllata Philochem AG ha concesso in licenza i diritti a livello mondiale su OncoACP3, un nuovo agente terapeutico e diagnostico per il trattamento del cancro alla prostata, a RayzeBio, società del gruppo Bristol-Myers Squibb, per un valore fino a 1,35 miliardi di dollari più royalties.

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.

The MedChem division of the Italian Chemical Society (SCI) awarded two Prizes to Philochem employees: Samuele Cazzamalli (Head of Chemistry) and Sara Puglioli (Research Scientist)

Recent Posts

Recent Comments

Legal